TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02825173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G
Description: Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques
Study: NCT03097484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lavender and chamomile essential oils
Description: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Study: NCT01247285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: 90 mg Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROZAC WEEKLY®
Description: 90 mg Capsules
Study: NCT02786550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
Study: NCT00629733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO-14
Study: NCT00461513

Intervention type: BEHAVIORAL
Intervention: Intervention
Description: Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
Study: NCT02686684

Intervention type: DRUG
Intervention: Dimethyl fumarate
Study: NCT02109640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targinact
Description: Post-operative analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Postoperative analgesia
Study: NCT00141219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 150-600mg/day, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01009151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Self Care Tracker
Description: Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Care Self Tracker
Description: Web-based Home Tele-monitoring System
Study: NCT02280369

Intervention type: DEVICE
Intervention: Automated abdominal binder
Description: Inflatable abdominal binder
Study: NCT04108052

Intervention type: RADIATION
Group type: OTHER
Intervention: Low CT scanner without injection dose
Description: CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
Study: NCT02109640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic segmental colectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic segmental colectomy
Study: NCT04108052

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultra-low dose CT scanner without injection
Description: CT acquisition will be performed at 80 kVp for patient with a body mass index\<30, and 100 kVp with a body mass index\>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
Study: NCT04458129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with polyethylene glycol (Macrogol 4000)
Description: 3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
Study: NCT02646007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSC transplantation
Description: Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
Study: NCT03033225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS-guided PDT
Study: NCT03155126

Intervention type: OTHER
Intervention: Fluid resuscitation
Description: Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium

Intervention type: OTHER
Intervention: Fluid resuscitation
Description: Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
Study: NCT03820882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catfish
Description: Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR
Description: Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
Study: NCT03145311

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Study: NCT01366326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Subcutaneous MNTX
Study: NCT00626275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859
Study: NCT03033225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo fluorescence imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo EUS-guided PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV
Study: NCT00626275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04001543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunomodulating oral supplementation
Description: Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sip feed control
Description: Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
Study: NCT02360826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Study: NCT02192125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REWIRE-System
Description: The REWIRE rehabilitation platform consists of three hierarchical components:~1. patient station (PS), which is installed in the home environment of the patient:~   Includes:~   Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~2. Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~   Includes:~   Laptop MySQL- database~3. station networking (NS), which allows a combination of a several of HS. database
Study: NCT02360826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study: NCT04283071

Intervention type: DEVICE
Intervention: Boxed infrared gross kinematic assessment tool
Description: An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras

Intervention type: DEVICE
Intervention: Boxed infrared gross kinematic assessment tool
Description: An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
Study: NCT00726648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 50mg capsules, 100mg bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250mg capsules, 500mg bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250mg capsules, 1000mg bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250mg capsules, 1000mg daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsules for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsules for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsules for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsules for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules for 4 weeks
Study: NCT02544568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
Study: NCT03596866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib Tablets.
Study: NCT02544568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
Study: NCT03596866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alectinib
Description: Alectinib Capsules.
Study: NCT05774834

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01544426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy and endometrial snip
Description: Office hysteroscopy with endometrial snip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: Office hysteroscopy
Study: NCT02489071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Program
Study: NCT00744926

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
Study: NCT01434173

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days

Intervention type: DRUG
Intervention: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Description: Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
Study: NCT02424617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bemcentinib
Description: Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bemcentinib
Description: Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bemcentinib
Description: Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: bemcentinib
Description: Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
Study: NCT02696265

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFAE guided ablation
Description: CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI guided ablation
Description: Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
Study: NCT04440878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mulligan TSLR technique
Description: Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
Study: NCT05065905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT01844453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
Study: NCT00586859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDO Full-thickness Plicator
Description: The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
Study: NCT04680806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 2780 nm
Description: The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser 940 nm
Description: The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
Study: NCT01655693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 20 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 30 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care
Study: NCT02098330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba & Methylprednisolone
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
Study: NCT04517149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-125 IVT Injection
Description: 4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-125 IVT Injection
Description: 4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.

Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: Natural History
Study: NCT00751361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rheopheresis / double filtration plasmapheresis
Description: Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.